Nanomed (also known as Nanomedical Diagnostics) is a medtech company developing graphene biosensors, tools for small molecule drug discovery and development. It offers an electrical assay based on proprietary Field Effect Biosensing (FEB) technology that detects molecular interactions without the use of optics or labeling. This technology delivers sensitive label-free binding confirmation of biomolecular interactions for accelerated drug discovery.
TypeSubsidiary
Parent CompanyCardea Bio
Founded2013
Websitenanomedical.com
Cybersecurity ratingAMore
Nanomed was founded in 2013

Viewing summary data as a guest

Sign up for free to see all data

Nanomed Financials and Metrics

Summary Metrics

Founding Date

2013

Total Funding

$2.2 m

Investors

In total, Nanomed had raised $2.2 m. Nanomed is a subsidiary of Cardea Bio

Nanomed Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Nanomed Online and Social Media Presence

Embed Graph

Nanomed Frequently Asked Questions

  • When was Nanomed founded?

    Nanomed was founded in 2013.

  • How many employees does Nanomed have?

    Nanomed has 9 employees.

  • Who are Nanomed competitors?

    Competitors of Nanomed include Advanced NanoTherapies, Nanotis and Nano Tech Projects.